TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 9267946
Drug: Dopexamine infusion
Normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopexamine infusion at all rates (0.75, 1.5, 3.0, and 6.0 microg/kg/min)
Study: 3302866
Drug: Cefotaxime IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime IV (100 mg.kg‐1 D‐1) plus netilmicin (4 mg.kg‐1 D‐1)
Study: 3302866
Drug: Amoxicillin/clavulanic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanic acid IV (100/10 mg.kg‐1 D‐1) plus netilmicin (4 mg.kg‐1 D‐1)
Study: 30110194
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg
Study: 27269741
Drug: Nivolumab 1
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 1 mg/kg plus ipilimumab 1 mg/kg
Study: 27622997
Drug: Nivolumab 1
Normalized name: nivolumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg
Study: 30110194
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg plus ipilimumab 1 mg/kg
Study: 18680975
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy schemes
Study: 12829908
Drug: Daclizumab 1
Normalized name: daclizumab 150 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclizumab 1 mg/kg immediately after liver transplantation
Study: 10791000
Drug: Conventional full-dose
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional full-dose docetaxel (FD) 60 mg/m2 every 3 or 4 weeks (group I)
Study: 10791000
Drug: Low-dose weekly
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose weekly docetaxel (LD) 20-30 mg/m2 every week (group II)
Study: 10791000
Drug: Low-dose weekly
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose weekly docetaxel (LD) 20-30 mg/m2 weekly with oral 5'-DFUR 600-1,200 mg per day (LD + D, group III)
Study: 20664343
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs (ibuprofen 800 mg twice a day for 10 days)
Study: 27196998
Drug: Morphine administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morphine administration
Study: 31977567
Drug: Lanreotide autogel/depot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lanreotide autogel/depot 120 mg
Study: 25249172
Drug: Povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone iodine solution (0.5 mg/mL)
Study: 19186714
Drug: Routine chemotherapeutic
Normalized name: Other chemotherapeutics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine chemotherapeutic program of western medicine
Study: 3930683
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 1-[13C]acetate
Study: 3930683
Drug: Rectal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Rectal administration of 1-[13C]acetate
Study: 31514191
Drug: Physiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physiotherapy plus intra-articular methylprednisolone injection
Study: 23970941
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (8 ounces daily for 4 weeks)
Study: 23970941
Drug: Placebo drink
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo drink (flavor-matched, 8 ounces daily for 4 weeks)
Study: 8630199
Drug: Mexiletine (450
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mexiletine (450 mg/day)
Study: 6331138
Drug: Cronassial (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cronassial (20 mg daily intramuscularly for 6 weeks)
Study: 25475245
Drug: Individualised self‐management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualised self‐management support for patients and feedback on use of evidence‐based HF therapies (EBT) to physicians.
Study: 25475245
Drug: Patient education,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient education, support, and self‐management training for diet and medication adherence by a trained nurse through 11 interactive sessions over a 4‐month period.
Study: 20637971
Drug: Linagliptin 10
Normalized name: empagliflozin-linagliptin 10 mg-5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 10 mg single dose
Study: 20637971
Drug: Linagliptin 5
Normalized name: linagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 5 mg multiple doses
Study: 20637971
Drug: Linagliptin 10
Normalized name: empagliflozin-linagliptin 10 mg-5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin 10 mg multiple doses
Study: 20637971
Drug: Linagliptin (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linagliptin (various doses)
Study: 11952447
Drug: Group 0
Normalized name: meningococcal group B vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 0 (modified supine position immediately after spinal injection)
Study: 8592998
Drug: Standard co-trimoxazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard co-trimoxazole therapy without monitoring (5 mg/kg trimethoprim and 25 mg/kg sulfamethoxazole every 6 h for 2 days, then every 8 h for 21 days)
Study: 368306
Drug: 2.5 percent
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 percent solution (double blind study)
Study: 368306
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of drugs (protocol at United Hospitals Medical Center)
Study: 26798083
Drug: Injection volume
Normalized name: VOLUME EXPANDERS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection volume up to 800 µL
Study: 19281585
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg mifepristone daily for three months
Study: 17229243
Drug: Immediate-release omeprazole
Normalized name: aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immediate-release omeprazole (IR-OME)
Study: 12001978
Drug: Advice to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Advice to increase soluble fibre intake to 8.0 g day(‐1) (fruit, vegetables and oats)
Study: 27804310
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg oral mifepristone plus 400 μg misoprostol per vaginally concurrently (group A)
Study: 27804310
Drug: Misoprostol administered
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol administered after 48 hours (group B)
Study: 21169226
Drug: DHA supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: DHA supplementation (1200 mg/d)
Study: 18460568
Drug: Triflusal (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triflusal (two dose levels)
Study: 8873586
Drug: Desmin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmin 100 mg once daily by subcutaneous route (36 patients)
Study: 8873586
Drug: Desmin 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmin 100 mg twice a day by subcutaneous route (33 patients)
Study: 8873586
Drug: Desmin 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desmin 200 mg once daily by intramuscular route (31 patients)
Study: 2895125
Drug: Nizatidine 75
Normalized name: nizatidine 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nizatidine 75 mg bid
Study: 2567740
Drug: Cimetidine 300
Normalized name: cimetidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 300 mg qid
Study: 18001246
Drug: Sub-tenon triamcinolone
Normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sub-tenon triamcinolone acetonide (STA) injection
Study: 16250568
Drug: Emdogain (Biora)
Normalized name: Biore
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emdogain (Biora) combined with surgical treatment (SPP flap)
Study: 16250568
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment alone (SPP)
Study: 12551742
Drug: Cholecystokinin tetrapeptide
Normalized name: cholecystokinin
DrugBank: Cholecystokinin (DB08862)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cholecystokinin tetrapeptide (CCK‐4) infusion
Study: 7975833
Drug: HIV‐1LAV gp160
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV‐1LAV gp160 live recombinant vaccinia virus priming followed by a booster injection with a baculovirus‐expressed HIV‐1LAV recombinant gp160 candidate vaccine
Study: 29033099
Drug: Cabazitaxel (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabazitaxel (25 mg/m2 IV every 21 days) plus prednisone (10 mg daily)
Study: 21555815
Drug: Drug Conservation
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug Conservation (DC) arm
Study: 17256437
Drug: Peripheral parenteral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral parenteral nutrition (PPN) for 7 days perioperatively
Study: 17256437
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (oral diet reintroduction on the fourth postoperative day)
Study: 10862159
Drug: Amiloride nebulized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride nebulized solution three times daily for 6 months
Study: 10862159
Drug: Placebo nebulized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo nebulized solution three times daily for 6 months
Study: 28903966
Drug: Selective laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective laser trabeculoplasty (SLT) followed by conventional medical therapy as required
Study: 31488427
Drug: Topical medication
Normalized name: Procto-Med Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical medication
Study: 16003515
Drug: carteolol 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: carteolol 2% regular twice daily for 2 months
Study: 8605790
Drug: Pentoxifylline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (1 mg/kg followed by an infusion of 1.5 mg/kg/hr for 24 hrs)
Study: 3097109
Drug: Astemizole (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astemizole (10 mg)
Study: 1401653
Drug: Terfenadine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terfenadine (60 mg)
Study: 6128019
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antihistamine)
Study: 28922099
Drug: Probiotic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic supplementation (Lactobacillus acidophilus, Lactobacillus casei, Bifidobacterium bifidum, Lactobacillus fermentum; 2 × 10^9 colony‐forming units/g each; n = 20)
Study: 15572850
Drug: Oral zafirlukast
Normalized name: Zafirlukast
DrugBank: Zafirlukast (DB00549)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral zafirlukast (40 mg/day) in addition to budesonide for 6 weeks
Study: 8995587
Drug: Suramin treatment
Normalized name: suramin
DrugBank: Suramin (DB04786)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Suramin treatment
Study: 12087908
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment program (synchronous plasmapheresis, large-dose methotrexate and methylprednisolone)
Study: 7780243
Drug: High cholesterol
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High cholesterol formula (30 mg/dl cholesterol)
Study: 7780243
Drug: Breast milk
Normalized name: BREAST MILK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Breast milk (mean cholesterol content 15.3 mg/dl)
Study: 2141104
Drug: Salbutamol, 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol, 2.5 mg
Study: 2141104
Drug: Ipratropium, 0.250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipratropium, 0.250 mg
Study: 30945991
Drug: Weight training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight training combined with pelvic floor muscle training (moderate intensity, twice a week for 12 weeks)
Study: 30276500
Drug: Erenumab 70
Normalized name: Erenumab 70 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erenumab 70 mg (CM)
Study: 25688120
Drug: Standard-dose temozolomide
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Standard-dose temozolomide
Study: 25151418
Drug: Augmented therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmented therapy (parent training, stimulant medication, and risperidone)
Study: 25151418
Drug: Basic therapy
Normalized name: Basic Fuchsin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basic therapy (parent training, stimulant medication, and placebo)
Study: 22376026
Drug: 0.2% chlorhexidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2% chlorhexidine gluconate (CHX) oral swabbing four times/day
Study: 15631278
Drug: Previous monotherapy
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Previous monotherapy (PM) plus hydrochlorothiazide (HCTZ) 12.5 mg
Study: 11603446
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 100 mL 0.9% NaCl solution (25 mL/h) at the same time points
Study: 16105426
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy + NIPPV (Bi-level positive airway pressure mode)
Study: 2074867
Drug: Nimesulide suppositories
Normalized name: nimesulide Rectal Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nimesulide suppositories
Study: 7005654
Drug: Detartrasis alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detartrasis alone (not followed by regular oral hygiene)
Study: 26350034
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group receiving: 28,000 IU cholecalciferol/wk for 8 weeks before surgery, 16,000 IU/wk and 1000 mg calcium monocitrate/d after surgery, daily BMI‐adjusted protein supplementation and physical exercise
Study: 22917822
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (not administered landiolol hydrochloride)
Study: 20430451
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (NS) treatment (same duration as intervention)
Study: 16121634
Drug: Karyometric measurements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Karyometric measurements from biopsies of rectal mucosa
Study: 10889166
Drug: Lamivudine 100
Normalized name: lamivudine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lamivudine 100 mg daily for 2 years
Study: 9364700
Drug: Combined DTPa-HBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined DTPa-HBV vaccine
Study: 9364700
Drug: Extemporaneously mixed
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extemporaneously mixed DTPa and HBV vaccines
Study: 29388846
Drug: Low-dose extract
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose extract (400 mg/day)
Study: 26190177
Drug: R-A/L-C (anodal
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-A/L-C (anodal electrode placed over the right SMC and cathodal electrode over the left SMC)
Study: 24742019
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment of each institution
Study: 16670112
Drug: Magnesium sulphate
Normalized name: Magnesium sulphate
DrugBank: Magnesium (DB14513)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnesium sulphate 40 mg kg(‐1) i.v. as a bolus before induction and 15 mg kg(‐1) h(‐1) by continuous i.v. infusion during the operation
Study: 14563595
Drug: Low-dose metoprolol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose metoprolol (up to 10 mg)
Study: 11068993
Drug: H. pylori
Normalized name: H. PYLORI AGENTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: H. pylori eradication treatment (2-week triple therapy: amoxicillin, clarithromycin, omeprazole)
Study: 31533391
Drug: 7.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/kg tranexamic acid before upper tourniquet and after closure of incision, combined with flexion position of hip (30° to 45°) and knee (60° for 70°)
Study: 31533391
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg tranexamic acid injected before loosening tourniquet
Study: 19218297
Drug: Robot therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot therapy with physiotherapy (10 sessions, more than 5000 movements)
Study: 19218297
Drug: Robot therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot therapy with physiotherapy
Study: 11408508
Drug: Raloxifene 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raloxifene 120 mg/d
Study: 9600478
Drug: HRT (conjugated
Approvals — FDA: no, EMA: no, PMDA: no
Description: HRT (conjugated equine estrogen, 0.625 mg/d, and medroxyprogesterone acetate, 2.5 mg/d)
Study: 8273794
Drug: 4 x/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 x/day therapy of CBS (108 mg), tetracycline HCl (500 mg), and metronidazole (250 mg)
Study: 2537217
Drug: Trandolapril (0.125,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril (0.125, 0.25, 0.5, 1, 2, 4, 8, 16, 24, 32 mg)
Study: 4983855
Drug: Ampicillin or
Normalized name: ampicillin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin or no antibiotic
Study: 21301920
Drug: Methylprednisolone in
Normalized name: methylprednisolone Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone in combination with azathioprine (MP + Aza group)
Study: 19156159
Drug: Calcium-vitamin D(3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium-vitamin D(3) fortified milk (400 ml per day, approximately 1000 mg of calcium and 800 IU of vitamin D(3))
Study: 17474812
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment (assertive outreach community treatment, family psychoeducation, social skills training)
Study: 16377455
Drug: Integrated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated treatment
Study: 18485612
Drug: Individual-Based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual-Based Treatment (IBT)
Study: 17716321
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BoNTA) injection into frontal (10 U)
Study: 17716321
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BoNTA) injection into temporal (6 U)
Study: 17716321
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BoNTA) injection into glabellar (9 U)
Study: 17716321
Drug: Botulinum toxin
Normalized name: Botulinum toxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum toxin type A (BoNTA) injection into all three areas (total dose 25 U)
Study: 31718959
Drug: No bonding
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bonding agent
Study: 31718959
Drug: Pre‐treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre‐treatments
Study: 21778605
Drug: Bonding agent
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bonding agent
Study: 31718959
Drug: Interaction of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interaction of pre‐treatments and bonding agent
Study: 28552806
Drug: Probiotic combination
Normalized name: PROBIOTIC COMBINATION CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic combination
Study: 23265711
Drug: Cetuximab plus
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab plus chemotherapy
Study: 28595137
Drug: Control (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (chemotherapy without cetuximab)
Study: 9401097
Drug: Pinaverium bromide
Normalized name: pinaverium bromide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pinaverium bromide (50 mg) taken orally t.i.d. with food
Study: 3620281
Drug: 0.8 g
Normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g kg‐1 absolute ethanol orally
Study: 21256028
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose of vitamin D (880 IU/d)
Study: 21256028
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose of vitamin D (1600 IU/d)
Study: 18729731
Drug: Vitamin therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin therapy
Study: 7839898
Drug: Cyclophosphamide 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 600 mg/m2 intravenously (i.v.) on day 1
Study: 7839898
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of i.v. cyclophosphamide 600 mg/m2 on day 1 and cytosine arabinoside 100 mg/m2 12 hourly sc for days 1‐5
Study: 20565392
Drug: 0.568 mg
Normalized name: petrolatum 0.568 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.568 mg x ml(‐1) levobupivacaine plus sufentanil 0.45 microg x ml(‐1)
Study: 20565392
Drug: 1.136 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.136 mg x ml(‐1) levobupivacaine plus sufentanil 0.45 microg x ml(‐1)
Study: 16943467
Drug: Initial injection
Normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Initial injection of 30 ml of levobupivacaine 0.5% with adrenaline 1:200 000.
Study: 16943467
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of levobupivacaine 0.25% at a rate of 5 ml per hour after an initial injection of 30 ml of levobupivacaine 0.5% with adrenaline 1:200 000.
Study: 8571186
Drug: No heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No heparin prophylaxis
Study: 7259512
Drug: Intravenous calcium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous calcium chloride (0.5 mg/kg/min constant infusion)
Study: 18355325
Drug: Vildagliptin 50
Normalized name: vildagliptin 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin 50 mg once daily
Study: 23988802
Drug: Epidural corticosteroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural corticosteroid injection of 80 mg methylprednisolone acetate